TheBrief.Health
Menin inhibitors revumenib and ziftomenib target key leukemia-driving mutations, improving remission rates, enabling transplant opportunities, and advancing precision treatment for relapsed acute leukemias.
Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de TheBrief.Health!
$99 / mes después de la prueba. · Cancela cuando quieras.
515 episodios
Reflow Medical’s Retrievable Coronary Drug‑Eluting Stent Shows Early Promise in In‑Stent Restenosis
Reflow Medical’s retrievable sirolimus-eluting coronary scaffold aims to treat in-stent restenosis without permanent metal, potentially improving vessel healing while preserving future treatment options.
Neurovalens CEO Outlines Noninvasive Neuromodulation Plans
Neurovalens’ Modius platform brings noninvasive neuromodulation into clinical practice, offering home-based FDA-authorized therapies for insomnia, anxiety, PTSD, and weight management, while facing evidence, reimbursement, and adoption challenges.
Shifting Care in Acute Leukemia: The Dawn of Menin Inhibition
Clinician Adoption of AI to Detect LV Systolic Dysfunction in Everyday Practice
AI-powered ECG and ultrasound tools can identify silent left ventricular systolic dysfunction earlier, enabling timely evaluation, targeted treatment, and improved heart failure prevention and outcomes.
How Oral TKIs are Rewriting the Frontline and Pretreated Landscape in HER2-Mutant NSCLC
A new generation of oral HER2-targeted therapies is transforming advanced NSCLC care, delivering durable responses, brain metastasis control, and personalized treatment beyond traditional chemotherapy.
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de TheBrief.Health!